Last 12 months
Inside the activity.
1 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2018 Filed Mar 5, 2018 21:57 UTC |
UNITEDHEALTH GROUP INCDirector · Director by Deputization
|
ConversionClass B Units and Class B Common Stock · Derivative | 1,772,898 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-006359 · doc4.xml · derivative · entry 3 UNITEDHEALTH GROUP INC · CIK 0000731766 · Director · Director by Deputization 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 1,772,898 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015, by and among Evolent Health, Inc., Evolent Health, LLC and the holders from time to time of Class B Common Units (the "Class B Units") of Evolent Health, LLC listed in Exhibit A thereto (the "Exchange Agreement"), ABCO may exchange its Class B Units (along with a corresponding number of its Class B Common Stock) for Class A Common Stock of Evolent Health, Inc. on a one-for-one basis, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among Evolent Health, Inc., ABCO and the other members party thereto. F2 · price: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015, by and among Evolent Health, Inc., Evolent Health, LLC and the holders from time to time of Class B Common Units (the "Class B Units") of Evolent Health, LLC listed in Exhibit A thereto (the "Exchange Agreement"), ABCO may exchange its Class B Units (along with a corresponding number of its Class B Common Stock) for Class A Common Stock of Evolent Health, Inc. on a one-for-one basis, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among Evolent Health, Inc., ABCO and the other members party thereto. F3 · price: On March 5, 2018, The Advisory Board Company exchanged 1,772,898 Class B Units (along with 1,772,898 Class B Shares) for 1,772,898 shares of Class A Common Stock. F2 · derivative.exercise_date: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015, by and among Evolent Health, Inc., Evolent Health, LLC and the holders from time to time of Class B Common Units (the "Class B Units") of Evolent Health, LLC listed in Exhibit A thereto (the "Exchange Agreement"), ABCO may exchange its Class B Units (along with a corresponding number of its Class B Common Stock) for Class A Common Stock of Evolent Health, Inc. on a one-for-one basis, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among Evolent Health, Inc., ABCO and the other members party thereto. F3 · derivative.exercise_date: On March 5, 2018, The Advisory Board Company exchanged 1,772,898 Class B Units (along with 1,772,898 Class B Shares) for 1,772,898 shares of Class A Common Stock. F2 · derivative.expiration_date: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015, by and among Evolent Health, Inc., Evolent Health, LLC and the holders from time to time of Class B Common Units (the "Class B Units") of Evolent Health, LLC listed in Exhibit A thereto (the "Exchange Agreement"), ABCO may exchange its Class B Units (along with a corresponding number of its Class B Common Stock) for Class A Common Stock of Evolent Health, Inc. on a one-for-one basis, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among Evolent Health, Inc., ABCO and the other members party thereto. F3 · derivative.expiration_date: On March 5, 2018, The Advisory Board Company exchanged 1,772,898 Class B Units (along with 1,772,898 Class B Shares) for 1,772,898 shares of Class A Common Stock. F1 · ownership.direct: The Advisory Board Company, a Delaware corporation ("ABCO"), is the record and direct beneficial owner of the Class A Common Stock of Evolent Health, Inc. (including the Class A Common Stock issued upon the exchange of the Class B Units owned directly by ABCO). ABCO is a direct, wholly-owned subsidiary of OptumInsight, Inc., a Delaware corporation ("OptumInsight"), which is an indirect, wholly owned subsidiary of UnitedHealth Group Incorporated, a Delaware corporation ("UNH"). UNH and OptumInsight may be deemed to beneficially own the securities beneficially owned by ABCO. F1 · ownership.nature: The Advisory Board Company, a Delaware corporation ("ABCO"), is the record and direct beneficial owner of the Class A Common Stock of Evolent Health, Inc. (including the Class A Common Stock issued upon the exchange of the Class B Units owned directly by ABCO). ABCO is a direct, wholly-owned subsidiary of OptumInsight, Inc., a Delaware corporation ("OptumInsight"), which is an indirect, wholly owned subsidiary of UnitedHealth Group Incorporated, a Delaware corporation ("UNH"). UNH and OptumInsight may be deemed to beneficially own the securities beneficially owned by ABCO. Read SEC document |
| March 05, 2018 Filed Mar 5, 2018 21:57 UTC |
UNITEDHEALTH GROUP INCDirector · Director by Deputization
|
ConversionClass A Common Stock, par value $0.01 per share | 1,772,898 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-006359 · doc4.xml · nonDerivative · entry 2 UNITEDHEALTH GROUP INC · CIK 0000731766 · Director · Director by Deputization 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,861,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015, by and among Evolent Health, Inc., Evolent Health, LLC and the holders from time to time of Class B Common Units (the "Class B Units") of Evolent Health, LLC listed in Exhibit A thereto (the "Exchange Agreement"), ABCO may exchange its Class B Units (along with a corresponding number of its Class B Common Stock) for Class A Common Stock of Evolent Health, Inc. on a one-for-one basis, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among Evolent Health, Inc., ABCO and the other members party thereto. F3 · price: On March 5, 2018, The Advisory Board Company exchanged 1,772,898 Class B Units (along with 1,772,898 Class B Shares) for 1,772,898 shares of Class A Common Stock. F1 · ownership.direct: The Advisory Board Company, a Delaware corporation ("ABCO"), is the record and direct beneficial owner of the Class A Common Stock of Evolent Health, Inc. (including the Class A Common Stock issued upon the exchange of the Class B Units owned directly by ABCO). ABCO is a direct, wholly-owned subsidiary of OptumInsight, Inc., a Delaware corporation ("OptumInsight"), which is an indirect, wholly owned subsidiary of UnitedHealth Group Incorporated, a Delaware corporation ("UNH"). UNH and OptumInsight may be deemed to beneficially own the securities beneficially owned by ABCO. F1 · ownership.nature: The Advisory Board Company, a Delaware corporation ("ABCO"), is the record and direct beneficial owner of the Class A Common Stock of Evolent Health, Inc. (including the Class A Common Stock issued upon the exchange of the Class B Units owned directly by ABCO). ABCO is a direct, wholly-owned subsidiary of OptumInsight, Inc., a Delaware corporation ("OptumInsight"), which is an indirect, wholly owned subsidiary of UnitedHealth Group Incorporated, a Delaware corporation ("UNH"). UNH and OptumInsight may be deemed to beneficially own the securities beneficially owned by ABCO. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:57 UTC |
UNITEDHEALTH GROUP INCDirector · Director by Deputization
|
SaleClass A Common Stock, par value $0.01 per share | 3,040,000 | $13.70 | $41,648,000.00 |
DisclosureSEC source: 0000899243-18-006359 · doc4.xml · nonDerivative · entry 1 UNITEDHEALTH GROUP INC · CIK 0000731766 · Director · Director by Deputization 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,088,167 F1 · ownership.direct: The Advisory Board Company, a Delaware corporation ("ABCO"), is the record and direct beneficial owner of the Class A Common Stock of Evolent Health, Inc. (including the Class A Common Stock issued upon the exchange of the Class B Units owned directly by ABCO). ABCO is a direct, wholly-owned subsidiary of OptumInsight, Inc., a Delaware corporation ("OptumInsight"), which is an indirect, wholly owned subsidiary of UnitedHealth Group Incorporated, a Delaware corporation ("UNH"). UNH and OptumInsight may be deemed to beneficially own the securities beneficially owned by ABCO. F1 · ownership.nature: The Advisory Board Company, a Delaware corporation ("ABCO"), is the record and direct beneficial owner of the Class A Common Stock of Evolent Health, Inc. (including the Class A Common Stock issued upon the exchange of the Class B Units owned directly by ABCO). ABCO is a direct, wholly-owned subsidiary of OptumInsight, Inc., a Delaware corporation ("OptumInsight"), which is an indirect, wholly owned subsidiary of UnitedHealth Group Incorporated, a Delaware corporation ("UNH"). UNH and OptumInsight may be deemed to beneficially own the securities beneficially owned by ABCO. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 17:13 UTC |
McGrane NicholasChief Financial Officer
|
GrantClass A Common Stock Option (right to buy) · Derivative | 52,609 | $0.00 Strike: $13.95 | $0.00 |
DisclosureSEC source: 0001628908-18-000005 · primary_doc.xml · derivative · entry 2 McGrane Nicholas · CIK 0001643086 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,609 Underlying: Class A Common Stock · 52,609 shares Expires 2028-02-01 F4 · derivative.exercise_date: Securities vest at a rate of 25% annually beginning February 1, 2019. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 17:13 UTC |
McGrane NicholasChief Financial Officer
|
GrantClass A Common Stock | 22,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000005 · primary_doc.xml · nonDerivative · entry 1 McGrane Nicholas · CIK 0001643086 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,990 F1 · security: Represents restricted stock units granted to Mr. McGrane pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 25% annually beginning February 1, 2019. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 22:24 UTC |
Weinberg JonathanGeneral Counsel
|
GrantClass A Common Stock Option (right to buy) · Derivative | 25,253 | $0.00 Strike: $13.95 | $0.00 |
DisclosureSEC source: 0001628908-18-000006 · primary_doc.xml · derivative · entry 2 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,253 Underlying: Class A Common Stock · 25,253 shares Expires 2028-02-01 F4 · derivative.exercise_date: Securities vest at a rate of 25% annually beginning February 1, 2019. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 22:24 UTC |
Weinberg JonathanGeneral Counsel
|
GrantClass A Common Stock | 10,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000006 · primary_doc.xml · nonDerivative · entry 1 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,775 F1 · security: Represents restricted stock units granted to Mr. Weinberg pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 25% annually beginning February 1, 2019. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:40 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
GrantClass A Common Stock Option (right to buy) · Derivative | 227,273 | $0.00 Strike: $13.95 | $0.00 |
DisclosureSEC source: 0001628908-18-000003 · primary_doc.xml · derivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,273 Underlying: Class A Common Stock · 227,273 shares Expires 2028-02-01 F4 · derivative.exercise_date: Securities vest at a rate of 25% annually beginning February 1, 2019. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:40 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
GrantClass A Common Stock | 96,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000003 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 898,357 F1 · security: Represents restricted stock units granted to Mr. Williams pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 25% annually beginning February 1, 2019. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 22:39 UTC |
Stone LydiaChief Accounting Officer
|
GrantClass A Common Stock | 7,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000008 · primary_doc.xml · nonDerivative · entry 1 Stone Lydia · CIK 0001654824 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,755 F1 · security: Represents restricted stock units granted to Ms. Stone pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 25% annually beginning February 1, 2019. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 22:32 UTC |
Peterson Thomas IIIChief Operating Officer
|
GrantClass A Common Stock Option (right to buy) · Derivative | 58,923 | $0.00 Strike: $13.95 | $0.00 |
DisclosureSEC source: 0001628908-18-000007 · primary_doc.xml · derivative · entry 2 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,923 Underlying: Class A Common Stock · 58,923 shares Expires 2028-02-01 F4 · derivative.exercise_date: Securities vest at a rate of 25% annually beginning February 1, 2019. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 22:32 UTC |
Peterson Thomas IIIChief Operating Officer
|
GrantClass A Common Stock | 25,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000007 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,868 F1 · security: Represents restricted stock units granted to Mr. Peterson pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 25% annually beginning February 1, 2019. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:59 UTC |
Blackley SethPresident
|
GrantClass A Common Stock Option (right to buy) · Derivative | 101,010 | $0.00 Strike: $13.95 | $0.00 |
DisclosureSEC source: 0001628908-18-000004 · primary_doc.xml · derivative · entry 2 Blackley Seth · CIK 0001643346 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,010 Underlying: Class A Common Stock · 101,010 shares Expires 2028-02-01 F4 · derivative.exercise_date: Securities vest at a rate of 25% annually beginning February 1, 2019. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:59 UTC |
Blackley SethPresident
|
GrantClass A Common Stock | 86,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000004 · primary_doc.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,227 F1 · security: Represents restricted stock units granted to Mr. Blackley pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 25% annually beginning February 1, 2019. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 17:44 UTC |
DUFFY MARY BRIDGETDirector
|
GrantClass A Common Stock | 6,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-17-000045 · primary_doc.xml · nonDerivative · entry 1 DUFFY MARY BRIDGET · CIK 0001570881 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,684 F1 · security: Represents restricted stock units granted to Dr. Duffy pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on October 2, 2018. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 16:15 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
SaleClass A Common Stock | 16,300 | $23.73 | $386,799.00 |
DisclosureSEC source: 0001628908-17-000039 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801,583 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $23.425-$24.100, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate prices within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 16:30 UTC |
WIGGINTON STEVECEO, Valence Health
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-17-000038 · primary_doc.xml · derivative · entry 3 WIGGINTON STEVE · CIK 0001232583 · CEO, Valence Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,680 Underlying: Class A Common Stock · 6,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2016. F4 · derivative.exercise_date: Tbe Class A Common Stock Options exercised vested on October 1, 2014. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 16:30 UTC |
WIGGINTON STEVECEO, Valence Health
|
SaleClass A Common Stock | 6,000 | $24.64 | $147,840.00 |
DisclosureSEC source: 0001628908-17-000038 · primary_doc.xml · nonDerivative · entry 2 WIGGINTON STEVE · CIK 0001232583 · CEO, Valence Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,411 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2016. F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.35-$24.90, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate prices within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 16:30 UTC |
WIGGINTON STEVECEO, Valence Health
|
Exercise / conversionClass A Common Stock | 6,000 | $3.84 | $23,040.00 |
DisclosureSEC source: 0001628908-17-000038 · primary_doc.xml · nonDerivative · entry 1 WIGGINTON STEVE · CIK 0001232583 · CEO, Valence Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2016. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 20:43 UTC |
Peterson Thomas IIIChief Operating Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 14,033 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-17-000037 · primary_doc.xml · derivative · entry 4 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,274 Underlying: Class A Common Stock · 14,033 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2017. F5 · derivative.exercise_date: The Class A Common Stock Options vested on December 1, 2014. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 20:43 UTC |
Peterson Thomas IIIChief Operating Officer
|
SaleClass A Common Stock | 26,507 | $26.00 | $689,182.00 |
DisclosureSEC source: 0001628908-17-000037 · primary_doc.xml · nonDerivative · entry 3 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,778 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2017. F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $26.00-$26.025, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 20:43 UTC |
Peterson Thomas IIIChief Operating Officer
|
SaleClass A Common Stock | 14,033 | $26.00 | $364,858.00 |
DisclosureSEC source: 0001628908-17-000037 · primary_doc.xml · nonDerivative · entry 2 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,285 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2017. F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $26.00-$26.025, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 20:43 UTC |
Peterson Thomas IIIChief Operating Officer
|
Exercise / conversionClass A Common Stock | 14,033 | $3.84 | $53,886.72 |
DisclosureSEC source: 0001628908-17-000037 · primary_doc.xml · nonDerivative · entry 1 Peterson Thomas III · CIK 0001643498 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2017. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 17:14 UTC |
McGrane NicholasChief Financial Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 1,667 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-17-000036 · primary_doc.xml · derivative · entry 3 McGrane Nicholas · CIK 0001643086 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,618 Underlying: Class A Common Stock · 1,667 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on September 14, 2016. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2016. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 17:14 UTC |
McGrane NicholasChief Financial Officer
|
SaleClass A Common Stock | 1,667 | $25.42 | $42,375.14 |
DisclosureSEC source: 0001628908-17-000036 · primary_doc.xml · nonDerivative · entry 2 McGrane Nicholas · CIK 0001643086 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,589 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on September 14, 2016. F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $25.25-$25.55, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 17:14 UTC |
McGrane NicholasChief Financial Officer
|
Exercise / conversionClass A Common Stock | 1,667 | $3.84 | $6,401.28 |
DisclosureSEC source: 0001628908-17-000036 · primary_doc.xml · nonDerivative · entry 1 McGrane Nicholas · CIK 0001643086 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on September 14, 2016. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 16:56 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
SaleClass A Common Stock | 1,250 | $25.27 | $31,587.50 |
DisclosureSEC source: 0001628908-17-000035 · primary_doc.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,883 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. F4 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $25.20-$25.50, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 16:56 UTC |
WILLIAMS FRANK JDirector · Chief Executive Officer
|
SaleClass A Common Stock | 15,050 | $24.72 | $372,036.00 |
DisclosureSEC source: 0001628908-17-000035 · primary_doc.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819,133 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2016. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.35-$25.15, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 16:27 UTC |
WIGGINTON STEVECEO, Valence Health
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-17-000034 · primary_doc.xml · derivative · entry 3 WIGGINTON STEVE · CIK 0001232583 · CEO, Valence Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,680 Underlying: Class A Common Stock · 6,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2016. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on October 1, 2014. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 16:27 UTC |
WIGGINTON STEVECEO, Valence Health
|
SaleClass A Common Stock | 6,000 | $25.07 | $150,420.00 |
DisclosureSEC source: 0001628908-17-000034 · primary_doc.xml · nonDerivative · entry 2 WIGGINTON STEVE · CIK 0001232583 · CEO, Valence Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,411 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2016. F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.925-$25.275, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 16:27 UTC |
WIGGINTON STEVECEO, Valence Health
|
Exercise / conversionClass A Common Stock | 6,000 | $3.84 | $23,040.00 |
DisclosureSEC source: 0001628908-17-000034 · primary_doc.xml · nonDerivative · entry 1 WIGGINTON STEVE · CIK 0001232583 · CEO, Valence Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2016. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 16:39 UTC |
TPG Growth II Advisors, Inc.10% owner · May be deemed 10% Owner (7)(8)
BONDERMAN DAVID10% owner · May be deemed 10% Owner (7)(8)
COULTER JAMES G10% owner · May be deemed 10% Owner (7)(8)
|
ConversionClass B Units and Class B Common Stock · Derivative | 3,619,531 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000903423-17-000440 · tpgrowthadii4evolent.xml · derivative · entry 3 TPG Growth II Advisors, Inc. · CIK 0001631279 · 10% owner · May be deemed 10% Owner (7)(8) BONDERMAN DAVID · CIK 0000860866 · 10% owner · May be deemed 10% Owner (7)(8) COULTER JAMES G · CIK 0001099776 · 10% owner · May be deemed 10% Owner (7)(8) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 659,970 Underlying: Class A Common Stock · 3,619,531 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: TPG Eagle Holdings, L.P. ("TPG Eagle") holds an aggregate of 659,970 Class B Common Units (the "Class B Units") of Evolent Health LLC and 659,970 shares of Class B Common Stock (the "Class B Shares") of Evolent Health, Inc. ("the Issuer"). F2 · security: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date. F3 · security: On June 28, 2017, TPG Eagle exchanged 3,619,531 Class B Units (along with 3,619,531 Class B Shares) for Class A Shares on a one-for-one basis. F2 · derivative.exercise_price: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date. F3 · derivative.exercise_price: On June 28, 2017, TPG Eagle exchanged 3,619,531 Class B Units (along with 3,619,531 Class B Shares) for Class A Shares on a one-for-one basis. F2 · price: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date. F3 · price: On June 28, 2017, TPG Eagle exchanged 3,619,531 Class B Units (along with 3,619,531 Class B Shares) for Class A Shares on a one-for-one basis. F2 · derivative.exercise_date: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date. F2 · derivative.expiration_date: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date. F1 · ownership.nature: TPG Eagle Holdings, L.P. ("TPG Eagle") holds an aggregate of 659,970 Class B Common Units (the "Class B Units") of Evolent Health LLC and 659,970 shares of Class B Common Stock (the "Class B Shares") of Evolent Health, Inc. ("the Issuer"). F2 · ownership.nature: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date. F5 · ownership.nature: David Bonderman and James G. Coulter are sole shareholders of TPG Growth II Advisors, Inc. ("Growth II Advisors" and, together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the general partner of each of the TPG Funds. F6 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each Reporting Person and TPG Fund disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's or TPG Fund's pecuniary interest therein, if any. F7 · ownership.nature: The TPG Funds have entered into a Stockholders Agreement, dated as of June 4, 2015 (as supplemented and amended, the "Stockholders Agreement"), with certain other holders (the "Holders") of Class A Shares, Class B Shares and Class B Units. Because of the relationship between the TPG Funds and the Holders as a result of the Stockholders Agreement, the Reporting Persons may be deemed, pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to beneficially own the Class A Shares, Class B Shares and Class B Units held in the aggregate by the Holders. Each Reporting Person and each TPG Fund disclaims beneficial ownership of the Class A Shares, Class B Shares and Class B Units held by the Holders. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 16:39 UTC |
TPG Growth II Advisors, Inc.10% owner · May be deemed 10% Owner (7)(8)
BONDERMAN DAVID10% owner · May be deemed 10% Owner (7)(8)
COULTER JAMES G10% owner · May be deemed 10% Owner (7)(8)
|
SaleClass A Common Stock | 4,279,325 | $25.87 | $110,706,137.75 |
DisclosureSEC source: 0000903423-17-000440 · tpgrowthadii4evolent.xml · nonDerivative · entry 2 TPG Growth II Advisors, Inc. · CIK 0001631279 · 10% owner · May be deemed 10% Owner (7)(8) BONDERMAN DAVID · CIK 0000860866 · 10% owner · May be deemed 10% Owner (7)(8) COULTER JAMES G · CIK 0001099776 · 10% owner · May be deemed 10% Owner (7)(8) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 120,304 F4 · ownership.nature: TPG Growth II BDH, L.P. ("Growth II BDH" and, together with TPG Eagle, the "TPG Funds") holds an aggregate of 120,304 Class A Shares. F5 · ownership.nature: David Bonderman and James G. Coulter are sole shareholders of TPG Growth II Advisors, Inc. ("Growth II Advisors" and, together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the general partner of each of the TPG Funds. F6 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each Reporting Person and TPG Fund disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's or TPG Fund's pecuniary interest therein, if any. F7 · ownership.nature: The TPG Funds have entered into a Stockholders Agreement, dated as of June 4, 2015 (as supplemented and amended, the "Stockholders Agreement"), with certain other holders (the "Holders") of Class A Shares, Class B Shares and Class B Units. Because of the relationship between the TPG Funds and the Holders as a result of the Stockholders Agreement, the Reporting Persons may be deemed, pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to beneficially own the Class A Shares, Class B Shares and Class B Units held in the aggregate by the Holders. Each Reporting Person and each TPG Fund disclaims beneficial ownership of the Class A Shares, Class B Shares and Class B Units held by the Holders. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 16:39 UTC |
TPG Growth II Advisors, Inc.10% owner · May be deemed 10% Owner (7)(8)
BONDERMAN DAVID10% owner · May be deemed 10% Owner (7)(8)
COULTER JAMES G10% owner · May be deemed 10% Owner (7)(8)
|
ConversionClass A Common Stock | 3,619,531 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000903423-17-000440 · tpgrowthadii4evolent.xml · nonDerivative · entry 1 TPG Growth II Advisors, Inc. · CIK 0001631279 · 10% owner · May be deemed 10% Owner (7)(8) BONDERMAN DAVID · CIK 0000860866 · 10% owner · May be deemed 10% Owner (7)(8) COULTER JAMES G · CIK 0001099776 · 10% owner · May be deemed 10% Owner (7)(8) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 4,399,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Pursuant to the terms of the Exchange Agreement dated as of June 4, 2015 by and among the Issuer, Evolent Health LLC and the holders from time to time of Class B Units listed in Exhibit A thereto (the "Exchange Agreement"), TPG Eagle may exchange all or a portion of its Class B Units (along with a corresponding number of its Class B Shares) at any time for shares of Class A Common Stock (the "Class A Shares") of the Issuer on a one-for-one basis initially, subject to adjustment pursuant to the terms of the Exchange Agreement and the Third Amended and Restated Operating Agreement entered into on June 4, 2015 among the Issuer, The Advisory Board Company, TPG Eagle and Ptolemy Capital, LLC as members. The right to exchange is not subject to an expiration date. F3 · price: On June 28, 2017, TPG Eagle exchanged 3,619,531 Class B Units (along with 3,619,531 Class B Shares) for Class A Shares on a one-for-one basis. F4 · ownership.nature: TPG Growth II BDH, L.P. ("Growth II BDH" and, together with TPG Eagle, the "TPG Funds") holds an aggregate of 120,304 Class A Shares. F5 · ownership.nature: David Bonderman and James G. Coulter are sole shareholders of TPG Growth II Advisors, Inc. ("Growth II Advisors" and, together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the general partner of each of the TPG Funds. F6 · ownership.nature: Because of the relationship between the Reporting Persons and the TPG Funds, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of the TPG Funds. Each Reporting Person and TPG Fund disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's or TPG Fund's pecuniary interest therein, if any. F7 · ownership.nature: The TPG Funds have entered into a Stockholders Agreement, dated as of June 4, 2015 (as supplemented and amended, the "Stockholders Agreement"), with certain other holders (the "Holders") of Class A Shares, Class B Shares and Class B Units. Because of the relationship between the TPG Funds and the Holders as a result of the Stockholders Agreement, the Reporting Persons may be deemed, pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to beneficially own the Class A Shares, Class B Shares and Class B Units held in the aggregate by the Holders. Each Reporting Person and each TPG Fund disclaims beneficial ownership of the Class A Shares, Class B Shares and Class B Units held by the Holders. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:15 UTC |
Blackley SethPresident
|
SaleClass A Common Stock | 15,000 | $25.22 | $378,300.00 |
DisclosureSEC source: 0001628908-17-000033 · primary_doc.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,205 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2016. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $25.00-$25.55, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 17:32 UTC |
McGrane NicholasChief Financial Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 1,667 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-17-000032 · primary_doc.xml · derivative · entry 4 McGrane Nicholas · CIK 0001643086 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,285 Underlying: Class A Common Stock · 1,667 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2016. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2016. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 17:32 UTC |
McGrane NicholasChief Financial Officer
|
SaleClass A Common Stock | 100 | $25.40 | $2,540.00 |
DisclosureSEC source: 0001628908-17-000032 · primary_doc.xml · nonDerivative · entry 3 McGrane Nicholas · CIK 0001643086 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,589 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2016. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 17:32 UTC |
McGrane NicholasChief Financial Officer
|
SaleClass A Common Stock | 1,567 | $24.53 | $38,438.51 |
DisclosureSEC source: 0001628908-17-000032 · primary_doc.xml · nonDerivative · entry 2 McGrane Nicholas · CIK 0001643086 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,689 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2016. F3 · price: The price reported on Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $24.05-$24.85, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 17:32 UTC |
McGrane NicholasChief Financial Officer
|
Exercise / conversionClass A Common Stock | 1,667 | $3.84 | $6,401.28 |
DisclosureSEC source: 0001628908-17-000032 · primary_doc.xml · nonDerivative · entry 1 McGrane Nicholas · CIK 0001643086 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2016. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:24 UTC |
Payson NormanDirector
|
GrantClass A Common Stock | 4,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-17-000030 · primary_doc.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,825 F1 · security: Represents restricted stock units granted to Mr. Payson pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 8, 2018 and the date of the company's 2018 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:55 UTC |
D'Amato MichaelDirector
|
GrantClass A Common Stock | 4,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-17-000027 · primary_doc.xml · nonDerivative · entry 1 D'Amato Michael · CIK 0001672282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,753 F1 · security: Represents restricted stock units granted to Mr. D'Amato pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 8, 2018 and the date of the company's 2018 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:40 UTC |
Holder DianeDirector
|
GrantClass A Common Stock | 4,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-17-000026 · primary_doc.xml · nonDerivative · entry 1 Holder Diane · CIK 0001642976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,825 F1 · security: Represents restricted stock units granted to Ms. Holder pursuant to the Evolent Health, Inc. Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 8, 2018 and the date of the company's 2018 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 17:15 UTC |
Farner DavidDirector
|
GrantClass A Common Stock | 4,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-17-000029 · primary_doc.xml · nonDerivative · entry 1 Farner David · CIK 0001642786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,825 F1 · security: Represents restricted stock units granted to Mr. Farner pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 8, 2018 and the date of the company's 2018 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 17:35 UTC |
Felt Bruce C. Jr.Director
|
GrantClass A Common Stock | 4,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-17-000031 · primary_doc.xml · nonDerivative · entry 1 Felt Bruce C. Jr. · CIK 0001410700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,825 F1 · security: Represents restricted stock units granted to Mr. Felt pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 8, 2018 and the date of the company's 2018 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:30 UTC |
SAMET KENNETH ADirector
|
GrantClass A Common Stock | 4,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001359252-17-000002 · primary_doc.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,420 F1 · security: Represents restricted stock units granted to Mr. Samet pursuant to Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 8, 2018 and the date of the company's 2018 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:08 UTC |
Scott CherylDirector
|
GrantClass A Common Stock | 4,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-17-000028 · primary_doc.xml · nonDerivative · entry 1 Scott Cheryl · CIK 0001656979 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,943 F1 · security: Represents restricted stock units granted to Ms. Scott pursuant to the Evolent Health, Inc. Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 8, 2018 and the date of the company's 2018 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 07, 2017 Filed Jun 8, 2017 16:38 UTC |
McGrane NicholasChief Financial Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001643086-17-000004 · primary_doc.xml · derivative · entry 4 McGrane Nicholas · CIK 0001643086 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,952 Underlying: Class A Common Stock · 10,000 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2016. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2016. Read SEC document |
| June 07, 2017 Filed Jun 8, 2017 16:38 UTC |
McGrane NicholasChief Financial Officer
|
SaleClass A Common Stock | 10,000 | $27.01 | $270,100.00 |
DisclosureSEC source: 0001643086-17-000004 · primary_doc.xml · nonDerivative · entry 3 McGrane Nicholas · CIK 0001643086 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,589 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2016. F3 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $27.00-$27.025, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 07, 2017 Filed Jun 8, 2017 16:38 UTC |
McGrane NicholasChief Financial Officer
|
Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001643086-17-000004 · primary_doc.xml · nonDerivative · entry 2 McGrane Nicholas · CIK 0001643086 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2016. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 16:38 UTC |
McGrane NicholasChief Financial Officer
|
SaleClass A Common Stock | 495 | $25.75 | $12,746.25 |
DisclosureSEC source: 0001643086-17-000004 · primary_doc.xml · nonDerivative · entry 1 McGrane Nicholas · CIK 0001643086 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,589 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2016. F2 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.